REGENXBIO Inc. (NASDAQ:RGNX) Shares Acquired by American Century Companies Inc.

American Century Companies Inc. increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 8.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,026 shares of the biotechnology company’s stock after acquiring an additional 7,658 shares during the period. American Century Companies Inc. owned about 0.19% of REGENXBIO worth $735,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its position in shares of REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock worth $4,382,000 after purchasing an additional 37,055 shares in the last quarter. FMR LLC increased its stake in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares during the period. BNP Paribas Financial Markets lifted its holdings in REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock worth $214,000 after buying an additional 17,533 shares in the last quarter. Verition Fund Management LLC purchased a new position in REGENXBIO in the 3rd quarter valued at approximately $432,000. Finally, Stifel Financial Corp grew its stake in shares of REGENXBIO by 13.3% in the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock worth $1,566,000 after acquiring an additional 17,563 shares in the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RGNX has been the topic of several analyst reports. Leerink Partners set a $24.00 price objective on REGENXBIO in a research note on Tuesday, March 18th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Chardan Capital reissued a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, March 20th. HC Wainwright reduced their target price on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, March 17th. Finally, Morgan Stanley boosted their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.78.

REGENXBIO Stock Up 8.9 %

NASDAQ:RGNX opened at $5.89 on Friday. REGENXBIO Inc. has a 52-week low of $5.04 and a 52-week high of $19.38. The stock’s 50 day moving average price is $7.00 and its 200 day moving average price is $8.29. The company has a market capitalization of $295.01 million, a PE ratio of -1.17 and a beta of 1.26.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.26. The business had revenue of $21.21 million for the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. As a group, sell-side analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.